Open access

1269 Immunotherapy (IO) associated acute interstitial nephritis, and outcomes after re-challenge: a single center experience
Joseph Puthumana, Omar Elghawy, Bethany Horton, Varinder Kaur

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1404; DOI: 10.1136/jitc-2023-SITC2023.1269
1270 Predicting risk factors for severe immune-related adverse events requiring hospitalization from checkpoint inhibitors
Jordyn Silverstein, Michelle Wang, Francis Wright, Joy Huang, Jessica Santhakumar, Eva Duvalyan, Arabella Young, Daniel Kim, Kimberly De Dios, Sam Brondfield, Zoe Quandt

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1405-A1406; DOI: 10.1136/jitc-2023-SITC2023.1270
1271 Development of a functional cardiotoxicity assay for evaluating the safety of cell therapies
Benjamin Streeter, Sayem H Bhuiyan, George Huang, Denise Sullivan, Austin Passaro, Stacie Chvatal, Daniel Millard

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1407; DOI: 10.1136/jitc-2023-SITC2023.1271
1272 Two-year experience of BITOX: the Belgian multidisciplinary ImmunoTOXicity board, a nationwide initiative of the Belgian Society for Medical Oncology (BSMO)
Marthe Verhaert, Sandrine Aspeslagh

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1408; DOI: 10.1136/jitc-2023-SITC2023.1272
1273 Effect of systemic immunosuppression timing on overall survival among immune checkpoint inhibitor recipients
Guihong Wan, Nga Nguyen, Boshen Yan, Munachimso Amadife, Bonnie W Leung, Kimberly Tang, Shijia Zhang, Nikolai Klebanov, Feng Liu, Genevieve M Boland, Nicole R Leboeuf, Shawn Kwatra, Kun-Hsing Yu, Alexander Gusev, Yevgeniy R Semenov

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1409-A1410; DOI: 10.1136/jitc-2023-SITC2023.1273
1274 Infliximab for decompensated diabetes following immune checkpoint inhibitor therapy
Robert J Weber, Christine Kim, Adil Daud, Mark Anderson, Zoe Quandt

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1411; DOI: 10.1136/jitc-2023-SITC2023.1274
1275 Optimizing lipid nano-particle (LNP) design for mRNA drug delivery, efficacy, and dose prediction using mechanistic modeling
BC Narmada, Raunak Dutta, Bhairav Paleja, Madhav Channavazzala

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1412-A1413; DOI: 10.1136/jitc-2023-SITC2023.1275
1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC
Cornelius Böhm, Katja Lingelbach, Blanca Pablos, Simon Heinke, Simon Schallenberg, Rosemarie Krupar, Nader Aldoj, Suhas Pandhe, Luca Pizzagalli, Maximilian Gottschalk, Bartosz Wójtowicz, Stephan Tietz, Marion Rudolph, Yuko Ishii, Lukas Ruff, Sharon Ruane, Maximilian Alber, David Schaer, Emmanuelle di Tomaso, Vasiliki Pelekanou

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1414; DOI: 10.1136/jitc-2023-SITC2023.1276
1277 Self-supervised deep learning enables label-free high-dimensional morphology profiling of immune cell types
Stephane Boutet, Kiran Saini, Senzeyu Zhang, Ryan Carelli, Kevin B Jacobs, Amy Wong-Thai, Vivian Lu, Andreja Jovic, Maddison Masaeli, Anastasia Mavropoulos

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1415; DOI: 10.1136/jitc-2023-SITC2023.1277
1278 TME-IS: a holotomography-based integrated segmentation for comprehensive analysis of extracellular components and cells in the tumor microenvironments
Yoon Ho Choi, Ekaterina Redekop, Minji Kim, Tae Hyun Hwang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1416; DOI: 10.1136/jitc-2023-SITC2023.1278

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages